Investigation Raises More Questions About Avandia

On July 15 -- a day after the U.S. Food and Drug Administration completed two days of hearings on the diabetes drug Avandia -- a British advisory commission on drugs concluded that the product should be withdrawn from the market, according to an investigation conducted by BMJ. The Commission on Human Medicines' opinion was passed on to the U.K.'s regulatory authority, the Medicines and Healthcare Products Regulatory Agency (MHRA), which has now told BMJ that Avandia "no longer has a place on...Full Story
Commenting on this article is closed.